4/A: Ionis Pharmaceuticals Executive Eugene Schneider Corrects Stock Sale Details in Amended SEC Filing

Eugene Schneider, EVP, Chf Clinical Develop Ofcr of Ionis Pharmaceuticals, amends a previous SEC Form 4 filing to correct the number of shares sold on February 2, 2024.

Summary

• Eugene Schneider, an executive at Ionis Pharmaceuticals, filed an amended Form 4 with the SEC.
• The amendment corrects the number of shares sold on February 2, 2024, and the amount of shares beneficially owned following the transaction.
• The corrected filing shows that 2,106 shares of common stock were sold at a weighted average price of $49.59.
• Following the transaction, Mr. Schneider beneficially owns 47,659 shares.
• The shares were sold in multiple transactions at prices ranging from $49.58 to $49.60 inclusive.

Sentiment

Score: 5

Explanation: The document is a routine correction of a previously filed form, indicating a neutral sentiment.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's value and future prospects. This amended filing provides corrected information about a previous transaction.

Stakeholder Impact

• Shareholders may be interested in executive stock transactions as an indicator of management's confidence in the company.

Key Dates